Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Nanomedicines Innovation Network - NMIN

$18.5 million for 2019-25
About   |   News
Nanomedicines Innovation Network

Headquarters
University of British Columbia, Vancouver, British Columbia

Chief Executive Officer and Scientific Director
Christine Allen Christine Allen

Board Chair
Don EnnsDon Enns
Vice-President and Head of Global Drug Delivery, Evonik Industries

Advancing nanomedicines to defeat disease


The opportunity

Nanomedicines or “smart” medicines that employ various forms of nanotechnology, are poised to have a revolutionary impact on drug development. Nanomedicines will deliver drugs, such as anticancer drugs, more specifically to disease sites to dramatically improve efficacy, to reduce toxicity and also to enable gene therapies employing RNA and DNA with the potential to treat most human diseases. Further, diagnostics and imaging agents based on nanotechnology will allow us to detect disease earlier and monitor the effectiveness of therapy more accurately.

How NMIN is seizing the opportunity

The NanoMedicines Innovation Network (NMIN) establishes and mobilizes a network drawn from academia, industry and other not-for-profit research enterprises to maintain and improve Canada’s position as a global leader in developing next generation nanomedicines. NMIN develops novel therapeutics to cure high-burden human diseases and new diagnostics to detect disease more precisely; commercializes these products to bring health and economic benefits to Canadians; and trains the skilled workforce required by the growing nanomedicines industry.

Among the results

  • As of 2020-21, NMIN has made 32 research investments, including 24 research projects, 2 commercialization-facilitating research platforms, and 6 strategic research initiatives (including one COVID-19-related project) resulting in 7 patents filed and 369 publications.
  • NMIN has spun off three new companies and created 11 jobs, with the aim of creating 10 new companies and 100 new highly skilled jobs by 2024.
  • NMIN is uniting Canada's world-leading nanomedicine sector and partnering strategically across sectors to foster a robust nanomedicine ecosystem. NMIN has 97 partners (2020-21), leveraging $1.66 in partner contributions for every $1 of NCE investment in research.
  • NMIN leaders are actively contributing to the development of a Canadian biomanufacturing strategy in response to COVID vaccine shortages and NMIN is partnering nationally across sectors to support the development of Canada’s nanomedicines ecosystem.
  • NMIN has engaged 163 HQP toward preparing the next generation of nanomedicine scientists and entrepreneurs. In 2019-21, NMIN issued 9 HQP Advanced Training Certificates, offered 47 capacity-building sessions, made available 966 individual advanced capacity-building opportunities, and partnered with Mitacs to award 6 studentships.
  • NMIN has established two novel world-class Core Facilities that are currently catalyzing innovation in nanomedicines and that will continue to do so moving forward. They are: NanoCore, which provides state-of-the-art nanoparticle formulations and a standardized nanomedicines characterization service to enable the ready manufacture of potent therapies for R&D purposes; and PharmaCore, which supports in vitro and in vivo studies, as well as scale-up, stability testing and manufacturing to help confirm commercial potential of new therapeutic compounds.
  • NMIN has built research support resources, including an online repository of capacity-building and scientific presentation videos, and three interactive online IP management tools developed in collaboration with a patent agent with expertise in biotech and pharmaceutical IP.

Connect with NMIN

 

News